Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd. raised $105 million in a series C financing round to move candidates, starting with an anti-CD39 antibody, into clinical studies in the U.S. The funds will also support the company’s efforts in finding new mechanisms for cancer immunotherapy and potential partners, it said.
HONG KONG – Hummingbird Bioscience Pte. Ltd. has raised $125 million in a series C financing to further investments in its early stage pipeline, as well as support the clinical development of its two lead oncology programs.
Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd. raised $105 million in a series C financing round to move candidates, starting with an anti-CD39 antibody, into clinical studies in the U.S. The funds will also support the company’s efforts in finding new mechanisms for cancer immunotherapy and potential partners, it said.
LONDON – A year on from delivering positive phase IIb data, Oculis SA has raised $57 million in an oversubscribed series C, to take OCS-01, a topical nanoparticle formulation of dexamethasone, through two phase III trials.
Ceribell Inc. amassed $53 million in a series C fundraising round to broaden the footprint for its noninvasive brain monitor in U.S. hospitals and expand indications for its Rapid Response EEG. Longitude Capital and The Rise Fund led the round.
Being in a crowded space doesn’t bother recently installed Arch Oncology Inc. CEO Laurence Blumberg. As a matter of fact, he’s reassured by it. “There’s a lot of competition in CD47, that’s correct,” Blumberg told BioWorld. “But having been in industry for a long time, competition and the magnitude of that competition in pursuit of a target usually means there’s a good reason for that interest and that there’s compelling evidence it has utility.”
The race to tame COVID-19 has morphed from a sprint to a long game as companies continue their development to handle a pandemic that is becoming endemic to the planet. That’s the case with Adagio Therapeutics Inc. as it chases clinical studies and an emergency use authorization (EUA) for its monoclonal antibody, ADG-20, to treat and prevent COVID-19.
HONG KONG – Bispecific antibody startup Epimab Biotherapeutics Inc. has completed a $120 million series C financing, bringing it closer to a potential IPO next year. The Shanghai-based company said the new funds would help it move EMB-01 into phase II testing this year.
HONG KONG - Bispecific antibody startup Epimab Biotherapeutics Inc. has completed a $120 million series C financing, bringing it closer to a potential IPO next year. The Shanghai-based company said the new funds would help it move its EGFR/cMET-targeted bispecific candidate, EMB-01, into phase II testing this year, as well supporting the advancement of other clinical candidates and an expansion of its pipeline.
Variantyx Inc. raised $20 million in a series C financing led by GHS Fund (Quark Venture LP and GF Securities). The new funds are earmarked for the development of comprehensive tumor diagnostic solutions and sales expansion. Also taking part in the round were new investor IBM Ventures and existing investors Pitango Venture Capital, New Era Capital Partners and 20/20 Healthcare Partners. With this latest infusion, Variantyx has raised a total of $38 million.
RSS
